In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer. In one approach, the addition of ...

Wood exposed to space for approximately 10 months showed no change in weight and no erosion due to atomic oxygen. This ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

Their studies, including samples from human patients, indicated that anti-VEGF therapies may actually contribute to a lack of vision improvement by triggering the overexpression of a second ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.